Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide‐induced inflammation in mouse lung
- 3 February 1998
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 123 (4) , 631-636
- https://doi.org/10.1038/sj.bjp.0701649
Abstract
Our previous work demonstrated that bacterial lipopolysaccharide (LPS), administered by aerosol, induced tumour necrosis factor (TNF‐α) synthesis leading to the infiltration of neutrophils into mice lungs. The treatment of animals with prostaglandin E2 or dibutyryl cyclic AMP impaired both processes. In this study, the target cell for LPS and the modulation by cyclic AMP of TNF‐α production and neutrophil recruitment were investigated. One hour after inhalation of 2 ml of 0.3 mg ml−1 LPS, TNF‐α levels measured by an ELISA method increased in the bronchoalveolar lavage fluid (BALF) of BALB/c mice, reaching a maximal level 3 h after inhalation. The immunocytochemistry assay demonstrated that 1 h after inhalation, 21.2% of alveolar macrophages collected in the BALF were immunopositive for TNF‐α. When mice were pretreated, i.p., with 20 mg kg−1 rolipram, a selective inhibitor of phosphodiesterase type 4, TNF‐α levels in the BALF were significantly reduced and only 7.3% of alveolar macrophages were immunopositive for TNF‐α. Alveolar macrophages from rolipram‐treated mice collected 30 min after inhalation of LPS had a significant increase in the intracellular concentrations of cyclic AMP. This was accompanied by a marked reduction of TNF‐α levels in the BALF that were associated with a suppression of TNF‐α mRNA expression. Systemic treatment with 20 mg kg−1 rolipram almost completely inhibited the LPS‐induced neutrophil recruitment, whereas it did not significantly reduce the recruitment induced by rmTNF‐α. Our results indicate that alveolar macrophages may be the target cells for both the induction and control of the lung inflammatory response to LPS. They also suggest that systemic treatment with cyclic AMP‐elevating agents may be useful to control local inflammation resulting from inhalation of bacterial endotoxin. British Journal of Pharmacology (1998) 123, 631–636; doi:10.1038/sj.bjp.0701649Keywords
This publication has 28 references indexed in Scilit:
- Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipramBritish Journal of Pharmacology, 1996
- Effects of theophylline and rolipram on antigen‐induced airway responses in neonatally immunized rabbitsBritish Journal of Pharmacology, 1996
- Cicaprost and the type IV phosphodiesterase inhibitor, rolipram, synergize in suppression of tumor necrosis factor-α synthesisEuropean Journal of Pharmacology, 1996
- Suppression of eosinophil function by RP 73401, a potent and selective inhibitor of cyclic AMP-specific phosphodiesterase: comparison with rolipramBritish Journal of Pharmacology, 1995
- Characterization of cAMP-dependent inhibition of LPS-induced TNFα production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitorInternational Journal of Immunopharmacology, 1994
- Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide.The Journal of Experimental Medicine, 1993
- The effect of zardaverine, an inhibitor of phosphodiesterase isoenzymes III and IV, on endotoxin‐induced airway changes in ratsClinical and Experimental Allergy, 1993
- Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice.The Journal of Experimental Medicine, 1989
- Enzyme immunoassays of adenosine cyclic 3',5'-monophosphate and guanosine cyclic 3',5'-monophosphate using acetylcholinesteraseAnalytical Chemistry, 1989
- Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of EndotoxinScience, 1985